Programme Thesis
Y Combinator funds pre-seed startups with global ambition, providing $500k and intensive mentorship to help founders achieve product-market fit and raise follow-on capital. The programme exists to back exceptional founders—especially those with deep technical expertise—building high-growth companies, and its Fall 2026 batch prioritizes AI-driven ventures that can benefit from YC’s US-centric network and in-person San Francisco cohort.
Selection Criteria
- Founder quality: domain expertise, technical ability, resilience, and clarity of vision (YC invests in people first)
- Idea clarity: a compelling, well-articulated problem and solution that can scale
- Traction: proof-of-concept, early validation, or user growth (even pre-revenue)
- Market size: large, growing, and addressable market (biotech/pharma AI fits)
- Defensibility: technology moat (e.g., proprietary data, model performance, IP)
- Coachability: openness to feedback and iteration during the batch
- Team: solo founder is acceptable but may be scrutinized; YC prefers at least two co-founders
- Timing: readiness to relocate to San Francisco for Oct–Dec 2026 and commit full-time
Past Winners / Cohort Profiles
YC has funded hundreds of AI and biotech startups, including notable examples like OpenAI, Stripe, Airbnb, and DoorDash. Recent cohorts include deep-tech AI companies (e.g., Anysphere, valued at $60B), biotech platforms (e.g., Insitro, Recursion), and computational drug discovery startups. Typical archetypes: technical solo founders or small teams with breakthrough algorithms, strong academic or industry backgrounds, and early traction (prototype, benchmark results, or pilot interest).
Ideal Candidate Fingerprint
A technically brilliant founder (or duo) with deep domain expertise in AI and a high-impact sector like biotech, who has built a working prototype with clear performance advantages over existing methods. They demonstrate strong traction (e.g., benchmark beats SOTA, pharma partner interest), a massive addressable market, and the ability to articulate a compelling vision. They are coachable, ready to relocate to San Francisco full-time, and open to YC’s intense, iterative approach.
Recommended Framing
Eniola should lead with her unique dual expertise as a pharmacist-turned-ML engineer, positioning herself as the rare founder who understands both the biology of drug resistance and the power of protein language models. Highlight that her technology achieves 100% mutation coverage vs. ~18% for structure-limited tools and beats published SOTA (AUROC 0.804 vs. 0.70), solving a critical bottleneck in drug development. Emphasize the pre-validated proof-of-concept, the named pharma partners (Servier, Sanofi), and the clear roadmap to AUROC ≥0.70 on SKEMPI 3K, framing the venture as a capital-efficient, AI-first biotech platform ready to scale with YC’s network and $500k investment.
Watch Out
Solo founder status may be a disadvantage—YC strongly prefers teams and may question bandwidth for both technical and business development. The venture is not yet incorporated, which could raise concerns about legal readiness. Relocation to San Francisco for the batch is required, which may conflict with EU/Île-de-France plans. The application deadline is days away (July 27, 2026), leaving minimal time to prepare a strong submission. Late applications are accepted but without a guaranteed decision timeline.